September 20, 2017
FDA Warning Letter Response and Questions

FDA Hammers A Flaunter of the Rules Against Making and Treating Patients with Fat Tissue-derived Stem Cells – Part Four

In case you haven’t heard, Ms. Kristin Comella, Chief Scientific Officer of the US Stem Cell Clinic (USSCC) was the recipient of a Warning Letter from the FDA concerning her clinic’s use of collagenase to digest fat tissue from patients to produce a stem cell-containing preparation known as stromal vascular fraction (SVF). I reviewed the...
Read More